The scientist’s investigation covers issues in Receptor, Melanocortin, Endocrinology, Internal medicine and Melanocortin receptor. The Receptor study combines topics in areas such as Ventral tegmental area, Stereochemistry and Pharmacology. His Melanocortin research is mostly focused on the topic Melanocortin 3 receptor.
His research on Endocrinology frequently links to adjacent areas such as Antagonist. His work on Melanocyte-stimulating hormone, Anorectic and Adrenocorticotropic hormone as part of general Internal medicine research is frequently linked to Zona reticularis, thereby connecting diverse disciplines of science. His Melanocortin receptor research incorporates elements of Biophysics and Radioligand.
His scientific interests lie mostly in Receptor, Internal medicine, Melanocortin, Endocrinology and Biochemistry. Jarl E. S. Wikberg has included themes like Molecular biology, Stereochemistry, Pharmacology and Cell biology in his Receptor study. His work on Melanocortin receptor, Melanocortin 3 receptor and Melanocortins as part of general Melanocortin study is frequently connected to Melanocortin 1 receptor, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His Melanocortin 3 receptor research is multidisciplinary, incorporating perspectives in Radioligand Assay, Enzyme-linked receptor and COS cells. His study on Endocrinology is mostly dedicated to connecting different topics, such as Orexigenic. His study looks at the relationship between Biochemistry and fields such as Dengue virus, as well as how they intersect with chemical problems.
Jarl E. S. Wikberg mainly investigates Quantitative structure–activity relationship, Computational biology, Immunology, Biochemistry and Phragmalin. Jarl E. S. Wikberg combines subjects such as Drug, Drug repositioning, Decision tree, External validation and Drug discovery with his study of Computational biology. Immunology is closely attributed to Melanocortin in his study.
Melanocortin is a subfield of Receptor that Jarl E. S. Wikberg studies. His study focuses on the intersection of Biochemistry and fields such as Dengue virus with connections in the field of NS3, Substrate and Molecular biology. Jarl E. S. Wikberg interconnects Sexual dysfunction, Stereochemistry, Semisynthesis and Neobeguea mahafalensis in the investigation of issues within Phragmalin.
His primary areas of investigation include Biochemistry, Web server, Data mining, Quantitative structure–activity relationship and Support vector machine. His study in the field of Amino acid, D-amino acid and Innate immune system also crosses realms of Anticancer peptide and Broad spectrum. His Data curation study in the realm of Data mining interacts with subjects such as Signature.
His Quantitative structure–activity relationship study combines topics in areas such as Acetylcholinesterase inhibitor, Acetylcholinesterase, Neuroscience, Cholinergic and Dementia. His work in Support vector machine covers topics such as Decision tree which are related to areas like Computational biology and Genetics. His work deals with themes such as Chemogenomics, Bioinformatics and Drug repositioning, which intersect with Computational biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
New aspects on the melanocortins and their receptors
Jarl E.S. Wikberg;Ruta Muceniece;Ilona Mandrika;Peteris Prusis.
Pharmacological Research (2000)
Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair.
Helgi B. Schiöth;Siôn R. Phillips;Richard Rudzish;Mark A. Birch-Machin.
Biochemical and Biophysical Research Communications (1999)
Melanocortin receptors: perspectives for novel drugs.
Jarl E.S Wikberg.
European Journal of Pharmacology (1999)
Characterisation of the melanocortin 4 receptor by radioligand binding
H. B. Schiöth;R. Muceniece;J. E. S. Wikberg.
Pharmacology & Toxicology (1996)
Expression of melanocortin 1 receptor in periaqueductal gray matter.
Yun Xia;Jarl E. S. Wikberg;Vijay Chhajlani.
Major pharmacological distinction of the ACTH receptor from other melanocortin receptors
Helgi B. Schiöth;Vijay Chhajlani;Ruta Muceniece;Vija Klusa.
Life Sciences (1996)
Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo.
Ants Kask;Felikss Mutulis;Ruta Muceniece;Rein Pähkla.
Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction
Jarl E. S. Wikberg;Felikss Mutulis.
Nature Reviews Drug Discovery (2008)
Selective Antagonist for the Melanocortin 4 Receptor (HS014) Increases Food Intake in Free-Feeding Rats
Ants Kask;Lembit Rägo;Felikss Mutulis;Rein Pähkla.
Biochemical and Biophysical Research Communications (1998)
Characterisation of melanocortin receptor subtypes by radioligand binding analysis
Helgi B. Schiöth;Ruta Muceniece;Jarl E.S. Wikberg;Vijay Chhajlani.
European Journal of Pharmacology (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: